Research Topics
| JAMES BRUCE BUSSELSummaryAffiliation: Cornell University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Novel approaches to refractory immune thrombocytopenic purpuraJ B Bussel
Department of Pediatrics, Division of Hematology and Oncology, Weill Medical College of Cornell University, New York, NY 10021, USA
Blood Rev 16:31-6. 2002..Understanding these cellular immune responses in ITP may lead to the development of more specific immunoregulatory therapies for the management of this disease...- AMG 531, a thrombopoiesis-stimulating protein, for chronic ITPJames B Bussel
New York Presbyterian Hospital, New York, USA
N Engl J Med 355:1672-81. 2006..Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP... - Novel thrombopoietic agents: preliminary activity, potential benefitJames B Bussel
Weill Cornell Medical College, Division of Pediatric Hematology, Payson 609, 525 E. 68th Street, New York, NY 10021, USA
J Support Oncol 5:63-84. 2007 - Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debatesJames B Bussel
Division of Hematology, Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021 4853, United States
Blood Rev 22:33-52. 2008..While there have been many advances regarding the diagnosis and treatment of AIT, it is still difficult to predict the severity of disease and which therapy will be effective... 
Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspectiveSusan D Mathias
Health Outcomes Solutions, P, O, Box 2343 Winter Park, Florida 32790, USA
Health Qual Life Outcomes 6:13. 2008..The aim of this research is to develop a conceptual model to describe the impact of ITP and its treatment on patients' health-related quality of life (HRQoL)...- A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validationSusan D Mathias
Ovation Research Group, 188 Embarcadero, San Francisco, CA 94105, USA
Health Qual Life Outcomes 5:11. 2007..Therefore, we sought to develop and validate the ITP-Patient Assessment Questionnaire (ITP-PAQ) for adult subjects with ITP... 
EltrombopagJames B Bussel
Division of Pediatric Hematology Oncology, Department of Pediatrics in Obstetrics and Gynecology and in Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY 10044, USA
Cancer Treat Res 157:289-303. 2011..We review the first clinical studies with this agent, emphasizing the significant findings...- Treatment of immune thrombocytopenic purpura in adultsJames Bussel
Department of Pediatrics, Division of Hematology and Oncology, and Department of Pediatrics in Medicine and in Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Hematol 43:S3-10; discussion S18-9. 2006..When used as either monotherapy or in combination with conventional therapeutics, these treatments may offer a more tolerable side effect profile and improved clinical benefit compared to existing drugs... - Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpuraJames B Bussel
Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York 10021 4885, USA
Am J Hematol 82:192-8. 2007..The results suggest that IGIV-C infused at rates up to 0.14 mL/kg/min in patients with ITP is well tolerated... - A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopeniaJames B Bussel
Department of Pediatrics, Division of Hematology, Weill Medical College of Cornell University, New York, NY, USA
Blood 118:28-36. 2011..In this short-term study, romiplostim increased platelet counts in 88% of children with ITP and was well-tolerated and apparently safe. The trial was registered with http://www.clinicaltrials.gov as NCT00515203... - Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpuraJames B Bussel
Weill Cornell Medical College of Cornell University, New York, NY 10065, USA
N Engl J Med 357:2237-47. 2007..The pathogenesis of chronic idiopathic thrombocytopenic purpura (ITP) involves antibody-mediated platelet destruction and reduced platelet production. Stimulation of platelet production may be an effective treatment for this disorder... - Current approaches to the evaluation and management of the fetus and neonate with immune thrombocytopeniaJames B Bussel
Division of Pediatric Hematology Oncology, Weill Cornell Medical College New York Presbyterian Hospital, New York, NY 10065, USA
Semin Perinatol 33:35-42. 2009..Thus, the accurate diagnosis and appropriate management of this disorder are of extreme importance in perinatal medicine and will constitute the focus of this review... - Therapeutic approaches to secondary immune thrombocytopenic purpuraJames B Bussel
Platelet Disorders Center, Division of Pediatric Hematology Oncology, Weill Cornell Medical College of Cornell University, New York, NY 10021, USA
Semin Hematol 46:S44-58. 2009..Unlike primary ITP, treatment often must be tailored to the specific circumstance underlying the secondary ITP, even if the condition itself is incurable... - Diagnosis and management of the fetus and neonate with alloimmune thrombocytopeniaJ Bussel
Platelet Research and Treatment Program, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10065, USA
J Thromb Haemost 7:253-7. 2009..This creates a risk of in utero ICH even if there was not one in the previous pregnancy. There are new developments in AIT in regard to diagnosis, treatment, and screening which will be the focus of this review... - Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treatJames B Bussel
Department of Pediatrics, Weill Medical College of Cornell University, 525 E 68th Street, P695, New York, NY 10065, USA
Hematol Oncol Clin North Am 23:1329-41. 2009..Finally, current studies to augment therapy in newly diagnosed ITP patients to prevent chronic disease may lessen the number of patients in chronic disease category... - Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetusJames B Bussel
Department of Pediatrics and Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, NY 10065, USA
Am J Obstet Gynecol 203:135.e1-14. 2010..We sought to prevent intracranial hemorrhage (ICH) through antenatal management of alloimmune thrombocytopenia... - Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopeniaJames B Bussel
Department of Pediatrics, The New York Hospital, Cornell University Medical Center, New York, New York 10021, USA
Pediatr Blood Cancer 45:176-83. 2005..This study was undertaken to compare the outcome of cases of AIT to cases of neonatal thrombocytopenia shown not to be AIT and to identify clinical features that would facilitate the diagnosis... - Another interaction of the FcR system with IVIGJames B Bussel
Division of Pediatrics, Weill Medical College of Cornell University, New York Hospital, New York, NY 10021, USA
Thromb Haemost 88:890-1. 2002 - A pilot study of rhuIL-11 treatment of refractory ITPJ B Bussel
Weill Medical College of Cornell University New York Presbyterian Hospital, Division of Pediatric Hematology Oncology, New York, New York 10021, USA
Am J Hematol 66:172-7. 2001..Toxicity was substantial. The lack of platelet response to rhuIL-11 in this study does not exclude the possibility of better effects at other doses and/or in less refractory patients... - Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy?J B Bussel
Department of Pediatrics, Weill Medical College of Cornell University New York Presbyterian Hospital, New York, New York, USA
Am J Hematol 67:27-33. 2001..However, a good platelet response in adults to the last IV anti-D and a hemoglobin decrease >/=2.0 gm/dl both appeared to predict response to subsequent splenectomy... - IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of lifeJames B Bussel
New York Presbyterian Hospital, Payson 695, 525 East 68th Street, New York, New York 10021 4885, USA
Thromb Haemost 91:771-8. 2004..Viral safety monitoring for HIV, HCV, HBV and Parvovirus B19 showed no seroconversions on study. In conclusion, IGIV-C is as safe and efficacious as IGIV-S/D in treatment of ITP... - Alloimmune thrombocytopenia in the fetus and newbornJ B Bussel
Division of Pediatric Hematology Oncology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York 10021, USA
Semin Thromb Hemost 27:245-52. 2001..IVIG remains the basis of therapy but appears to require a higher dose (2 g/kg/week) and/or the addition of 1 mg/kg of prednisone in the highest risk cases, those with antenatal intracranial hemorrhage... - The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopeniaBenjamin Levy
Platelet Research and Treatment Program, Division of Pediatric Hematology Oncology, Weill Cornell Medical College, New York, New York, USA
Curr Opin Oncol 20:690-6. 2008..This review summarizes the history of the development of thrombopoietic agents and discusses their potential use in chemotherapy-induced thrombocytopenia... - Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trialRichard L Berkowitz
Department of Obstetrics and Gynecology, Columbia Presbyterian Medical Center, 622 West 168th Street, New York, NY 10032, USA
Obstet Gynecol 110:249-55. 2007..The study was limited to "standard-risk" patients, who were defined as women with documented alloimmune thrombocytopenia who had not delivered an infant with an intracranial hemorrhage in a prior pregnancy... - Overview of thrombopoietic agents in the treatment of thrombocytopeniaRachel Kobos
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Clin Lymphoma Myeloma 8:33-43. 2008..Development of these agents might also improve the management of diseases such as cancer and hepatitis C, whose current regimens are limited by the occurrence of thrombocytopenia... - Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparisonAndromachi Scaradavou
New York Blood Center, New York, New York, USA
Am J Hematol 82:335-41. 2007..Anti-D should be the first line therapy in HIV-positive, Rh+ patients, when antiretroviral agents are not indicated, not effective, or there is an urgent need to increase the platelet count... - Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trialJames B Bussel
Weill Cornell Medical College of Cornell University, New York, NY, USA
Lancet 373:641-8. 2009..This study assessed the efficacy, safety, and tolerability of once daily eltrombopag 50 mg, and explored the efficacy of a dose increase to 75 mg... - Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITPJames B Bussel
Department of Pediatrics, Division of Hematology, New York Presbyterian Hospital, NY, USA
Blood 113:2161-71. 2009..In conclusion, romiplostim increased platelet counts in most patients for up to 156 weeks without tachyphylaxis and had an acceptable safety profile. (ClinicalTrials.gov Identifier NCT00116688)... - Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 casesBethan Psaila
Department of Pediatric Hematology Oncology, Weill Cornell Medical Center and NewYork Presbyterian Hospital, New York, NY, USA
Blood 114:4777-83. 2009..Children with severe thrombocytopenia plus head trauma and/or hematuria appeared to be at particularly high risk of ICH. Aggressive treatment of these children may be appropriate... - Alloimmune thrombocytopenia: state of the art 2006Richard L Berkowitz
Department of Obstetrics and Gynecology, Columbia Presbyterian Medical Center, New York, NY 10032, USA
Am J Obstet Gynecol 195:907-13. 2006.... - Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapyKristen M Marks
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
J Acquir Immune Defic Syndr 52:595-9. 2009..Before potent antiretroviral therapy, thrombocytopenia was observed frequently. Little is known about risk factors for or severity and consequences of thrombocytopenia since establishment of highly effective therapy for HIV... - Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected childrenMary J Ward
Department of Pediatrics, Divisions of General Pediatrics and Hematology-Oncology, Weill Medical College of Cornell University, New York, New York, USA
Am J Perinatol 23:487-92. 2006..We speculate that platelets may possibly play a role in neurodevelopmental processes in the fetus... - Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatmentJulie Wang
Department of Pediatrics, Division of Allergy and Immunology, Mount Sinai Medical Center, New York, New York 10029, USA
J Pediatr 146:217-21. 2005..This study examined the efficacy and safety of rituximab in children with chronic immune thrombocytopenic purpura... - Maternal and neonatal characteristics associated with neonatal neutropenia in hypertensive pregnanciesGeeta Sharma
Department of Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, New York, USA
Am J Perinatol 26:683-9. 2009..7% versus 2.2% neutropenia in singletons (p < 0.001). Furthermore, multiple gestations with neutropenia had a higher incidence of sepsis than singletons with neutropenia... - Romiplostim: a second-generation thrombopoietin agonistClaudia S Cohn
Department of Pathology, NY Presbyterian Hospital, New York, NY, USA
Drugs Today (Barc) 45:175-88. 2009..In addition, antibodies that can stimulate the c-Mpl receptor are being engineered to act as potent TPO agonists. These and other drugs in preclinical development represent a new line of therapy for thrombocytopenic patients... - Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphismsNichola Cooper
Division of Hematology Oncology, Department of Pediatrics, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY 10021, USA
Br J Haematol 124:511-8. 2004.... - Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpuraEllinor I B Peerschke
Weill Cornell Medical College of Cornell University, New York, NY, USA
Br J Haematol 148:638-45. 2010..063). Thus, complement fixation may contribute to the thrombocytopenia of ITP by enhancing clearance of opsonized platelets from the circulation, and/or directly damaging platelets and megakaryocytes... - Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancyMarc Michel
Department of Pediatrics, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York, NY 10021, USA
Br J Haematol 123:142-6. 2003..The direct antiglobulin test was positive in three out of seven Rh+ newborns, none of whom was anaemic or jaundiced. Anti-D is effective and appears to be safe for both mother and fetus... - Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?Nichola Cooper
Department of Pediatrics, Division of Hematology Oncology, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
Blood 99:1922-7. 2002..Platelet count at study entry was the primary predictor of outcome... - Treatment with rituximab in benign and malignant hematologic disorders in childrenLisa B Giulino
Weill Medical College of Cornell University, Department of Pediatrics, Division of Hematology/Oncology, New York, NY 10021, USA
J Pediatr 150:338-44, 344.e1. 2007 - The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITPLemke K Page
Division of Pediatric Hematology Oncology, Weill Medical College of Cornell University, New York 10021, USA
Br J Haematol 138:245-8. 2007..The IBLS is a useful clinical tool for monitoring bleeding and may be used to aid the development of laboratory parameters that correlate with underlying bleeding propensity in thrombocytopenia... - 21. Immunohematologic disordersDeepa H Trivedi
Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 E. 67th Street, New York, NY 10031, USA
J Allergy Clin Immunol 111:S669-76. 2003..Other immune reactions include antibodies to clotting factors, which result in both thrombosis and hemorrhage, and hemolytic and nonhemolytic reactions during transfusion of blood products... - Refractory immune thrombocytopenic purpura: current strategies for investigation and managementBethan Psaila
Platelet Disorders Center, Division of Pediatric Hematology Oncology, Weill Cornell Medical College of Cornell University, New York, NY 10021, USA
Br J Haematol 143:16-26. 2008..Morbidity, mortality and heath-related quality of life are also discussed... - Differential diagnosis and management of thrombocytopenia in childhoodRosandra N Kaplan
Weill Medical College of Cornell University, Division of Pediatric Hematology/Oncology, New York Presbyterian Hospital/Cornell Medical Center, 525 East 68th Street, New York, NY 10021, USA
Pediatr Clin North Am 51:1109-40, xi. 2004..With each disease process, the pathophysiology as it is currently known is described and discussed... - The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraNichola Cooper
Division of Hematology Oncology, Departments of Pediatrics and Medicine, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY, USA
Br J Haematol 125:232-9. 2004..No changes in immunoglobulin levels or infectious complications were seen. In summary, rituximab was well tolerated with no immediate complications and induced a lasting, substantial response in 32% of adults with chronic ITP... - The effect of anti-CD40 ligand in immune thrombocytopenic purpuraVivek L Patel
Division of Pediatric Hematology Oncology, Weill Medical College of Cornell University, New York, NY, USA
Br J Haematol 141:545-8. 2008..The 24% (11/46) overall response rate demonstrates the potential role of CD40-CD40L in the pathogenesis of ITP... - Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpuraJin Yu
Laboratory of Complement Biology, New York Blood Center, New York, NY 10021, USA
Blood 112:1325-8. 2008..The impaired suppression was specific to Tregs as shown by cross-mixing experiments with T cells from controls. These data suggest that functional defects in Tregs contribute to breakdown of self-tolerance in patients with chronic ITP... - Fetal and neonatal cytopenias: what have we learned?James B Bussel
Department of Pediatrics, Division of Pediatric Hematology Oncology, New York Presbyterian Hospital, New York, New York 10021, USA
Am J Perinatol 20:425-31. 2003..Antenatal management of affected fetuses with treatment administered to the mother is now well established although studies are ongoing. Neutropenia is a complication of pre-eclampsia; the mechanism is still not well understood... - Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysisLinda J Butros
Department of Pediatrics, Columbia-Presbyterian Medical Center, New York, New York, USA
J Pediatr Hematol Oncol 25:660-4. 2003..ICH occurs more commonly in acute ITP but can occur years after diagnosis. A significant number of patients develop an ICH despite having already initiated steroid treatment of ITP... - Fc receptors in immune thrombocytopenias: a target for immunomodulation?Bethan Psaila
Platelet Disorders Center, Division of Pediatric Hematology Oncology, Weill Cornell Medical College of Cornell University, New York, New York 10021, USA
J Clin Invest 118:2677-81. 2008..These reports illustrate how a remarkably detailed molecular understanding of the FcR network may translate into new therapeutic strategies with high clinical impact... - Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)Donna M Boruchov
The Brookdale University Hospital and Medical Center Department of Pediatrics, Hematology Oncology, Brooklyn, NY, USA
Blood 110:3526-31. 2007..Combination chemotherapy is a useful approach for patients with ITP refractory to conventional treatments both for acute induction and for long-term maintenance therapy... - Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?Marc Michel
New York Presbyterian Hospital, Department of Pediatrics, Division of Pediatric Hematology Oncology, Weill Medical College of Cornell University, 525 East 68th St, New York, NY 10021, USA
Blood 103:890-6. 2004.... - Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of SykAnna Podolanczuk
Department of Medicine, New York Presbyterian Hospital, Columbia University Medical Center, New York 10032, USA
Blood 113:3154-60. 2009..In conclusion, inhibition of Syk was an efficacious means of increasing and maintaining the platelet count in half the patients with chronic refractory ITP. (ClinicalTrials.gov, no. NCT00706342)... - Elevated IgA and IgM anticardiolipin antibodies in acute Kawasaki diseaseMonesha Gupta
Division of Cardiology, Department of Pediatrics, New York Presbyterian Hospital, New York, N Y, USA
Cardiology 97:180-2. 2002..Elevation of IgA aCL has been reported in association with other vasculitides and IgA-secreting plasma cells have been demonstrated in the vascular tissue in Kawasaki disease...
Research Grants
- Novel Therapies in Hemostasis and TransfusionJames Bussel; Fiscal Year: 2007..Dr. James Bussel, as our site's Primary Investigator, is responsible for ensuring that all aspects of TMH Network protocols are followed. WEILL CORNELL MEDICAL CENTER/NEW YORK PRESBYTERIAN HOSPITAL CRITIQUES ..